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Natural killer cell receptors (NKRs) are germline-encoded transmembrane proteins that 
regulate the activation and homeostasis of NK cells as well as other lymphocytes. For 
γδ T cells, NKRs play critical roles in discriminating stressed (transformed or infected) 
cells from their healthy counterparts, as proposed in the “lymphoid stress-surveillance” 
theory. Whereas the main physiologic role is seemingly fulfilled by natural killer group 
2 member D, constitutively expressed by γδ T cells, enhancement of their therapeutic 
potential may rely on natural cytotoxicity receptors (NCRs), like NKp30 or NKp44, that 
can be induced selectively on human Vδ1+ T cells. Here, we review the contributions 
of NCRs, NKG2D, and their multiple ligands, to γδ T cell biology in mouse and human.
Keywords: γδ T cells, natural killer cell receptors, natural killer group 2 member D, natural cytotoxicity receptors, 
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inTRODUCTiOn
Natural killer cell receptors (NKRs) comprise various germline-encoded transmembrane proteins 
characterized for their capacity to regulate NK cell activation and homeostasis. This large family 
includes lectin-type receptors, natural cytotoxicity receptors (NCRs), and killer immunoglobulin 
receptors. The balance between activating and inhibitory signals derived from these receptors con-
trols NK cell functionality. Besides their roles for NK cells, some NKRs, most notably natural-killer 
group 2 member D (NKG2D), have been known for long to be expressed by some subsets of T cells 
(1), including γδ T cells (2). In fact, nearly all human γδ T cells, and most mouse γδ T cells, express 
NKG2D. Importantly, we, and others, have shown that NKG2D is a key determinant of tumor cell 
recognition by murine intraepithelial γδ T cells (3, 4), as well as human peripheral blood (2, 5) and 
tumor-infiltrating (6) γδ T cells.
By contrast to NKG2D, NCRs were initially thought to be NK cell-specific (7), although this has 
changed particularly with the discovery of innate lymphoid cells (ILCs) (8). In fact, the acquisition 
of an NK-like phenotype and functionality was earlier reported on human intestinal intraepithelial 
lymphocytes (IELs), particularly in celiac disease (9, 10). The NCRs expressed on αβ IELs trig-
gered interferon-γ (IFN-γ) secretion and degranulation (10), thus suggesting that IEL activation 
under inflammatory conditions favored the differentiation of “NK-like” effectors performing type 1 
cytotoxic functions in an NKR-mediated (and TCR-independent) manner. We have recently built on 
this to show that human γδ T cells, specifically of the Vδ1+ subset, can be induced to express NCRs 
upon TCR plus IL-15 (or IL-2) stimulation in vitro, and these NCRs enhanced the capacity to target 
tumor cells of multiple origins, both in vitro and in vivo [(11, 12), and unpublished data].
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In this mini-review, we will focus on the roles of NCRs, 
NKG2D, and their ligands for γδ T  cell biology in mouse and 
human.
nKG2D AnD iTS LiGAnDS
The best-characterized activating NKR is NKG2D. NKG2D is a 
C-type lectin-like transmembrane receptor, which recognizes a 
range of different major histocompatibility complex class (MHC) 
I-related self-ligands induced or upregulated by a variety of cellular 
stress events, and notably on infected or transformed epithelial 
cells (ECs) (13). In mice, two isoforms of NKG2D exist, NKG2D-
short (S) or NKG2D-long (L), while only the counterpart to the 
NKG2D-L isoform is expressed in human. The receptor func-
tions as an activating receptor only through its association with 
signaling adaptor proteins, which are determined by the isoform 
of NKG2D expressed. NKG2D-S can associate with both DAP10 
(recruits phosphatidylinositol 3-kinase) and DAP12 (activates 
tyrosine kinases Syk and ZAP70) while NKG2D-L is structurally 
incapable of associating with DAP12 and NKG2D-mediated 
signaling is mediated solely through DAP10 (14–16).
Engagement of NKG2D can trigger degranulation, cytotox-
icity, and/or cytokine production—the distinct outcome of the 
receptor ligation may be explained by differential isoform and 
adaptor protein expression. Whereas, mouse CD8+ αβ T  cells 
do not express DAP12 (and the exclusive NKG2D-DAP10 asso-
ciation serves as a costimulatory receptor), mouse epidermal γδ 
IELs constitutively express NKG2D-S, NKG2D-L, DAP10, and 
DAP12, and NKG2D ligation may trigger activity without TCR 
engagement (17).
Despite the different isoforms of NKG2D, the receptor is highly 
conserved with the receptors being 70% homologous between 
human and mouse, for example. NKG2D from one species can 
bind ligands from another (18). This is curious as the ligands are 
multiple and are both highly diverse in their amino-acid sequence, 
domain structure, membrane anchoring as well as exhibiting con-
siderable allelic variation, and a wide range of receptor-binding 
affinities (Figure 1A). NKG2D ligands identified so far in humans 
include the MHC class I-chain-related proteins A and B (MICA 
and MICB) and six different UL16-binding proteins. In mice, 
three subgroups of NKG2D ligands have been identified: five 
isoforms of retinoic acid early-inducible 1 (Rae-1) proteins, one 
murine UL16-binding protein-like transcript 1 (MULT1), and 
three different isoforms of H60 proteins (Figure 1A). Why the 
NKG2D receptor is so promiscuous and engaging with so many 
ligands is not know, however, there are indications that not all 
ligands are functionally equivalent and that the diversity may 
allow for unique tissue-specific and contextual functions (1).
nKG2D AS A CRiTiCAL DeTeRMinAnT 
OF MOUSe γδ T CeLL ACTivATiOn
Study of the NKG2D receptor is not only of huge academic inter-
est, but clearly has therapeutic importance both within cancer, 
infection, and autoimmunity. Study of this receptor has also 
given us fundamental insight into γδ T cell biology. The capacity 
of murine tissue γδ T cells to act solely on alterations of autolo-
gous stress-antigens, such as those of the NKG2D receptor, and 
thus survey the “health-status” of a given EC has been termed 
lymphoid stress-surveillance (LSS) (4, 20, 21) (Figure 1Bi,ii). LSS 
highlights an important function of γδ T cells as afferent sensors 
of cellular dysregulations and as initiators of local and systemic 
immunity—a clear distinction from conventional αβ T cell bio-
logy. The activation of tissue γδ T cells during LSS in situ occurs 
seemingly without TCR stimulation (4). However, an alternative 
explanation could be that the TCR is constitutively engaged in 
the tissue as was suggested by an elegant study visualizing the 
γδ TCR continually signaling in the skin epidermis (22). The 
self-ligand recognized by the Vγ5Vδ1 TCR was not identified in 
this study, however, the implication of a possible constitutive TCR 
engagement in the tissue could be a predisposition to respond 
rapidly to stress-induced ligands recognized by co-stimulatory 
receptors, such as NKG2D. Whether substituting or synergizing 
with TCR signaling, these (co)stimulators are of pivotal impor-
tance in initiating and tuning the γδ T cell response. Interestingly, 
while epidermal γδ IEL activate and respond rapidly in vivo to 
transgenic acute upregulation of Rae-1 on ECs (4) (Figure 1Bi), 
prolonged constitutive expression of Rae-1 (19) renders them 
hyporesponsive and they remain in a resting state (Figure 1Biii). 
It is not clear how this tuning of the γδ IEL responsiveness is 
regulated according to the length of NKG2D-ligand expression, 
but the “beneficial autoimmunity” displayed during acute stress 
responses may be detrimental in chronicity and could be regu-
lated by negative signals mediated by inhibitory NKRs, such as 
Ly49E and CD94-NKG2A (23). It would be of therapeutic value 
to understand when and how NKG2D-ligand hyporesponsive-
ness may occur as solid tumors, for example, can have long-term 
display of these ligands, which paradoxically could switch off 
resident tissue immune surveillance.
Natural killer group 2 member D clearly is a cytotoxic receptor 
and its engagement on γδ T cells has been shown in many murine 
studies to induce degranulation, cytotoxicity, and sometimes 
cytokine production (3, 17, 24). These studies all assessed γδ T cell 
function in isolation in vitro using γδ T cell lines. However, NKG2D 
ligands may not always function to generate cytotoxic responses 
in  situ and the outcome of NKG2D receptor ligation is almost 
certainly context dependent. The different ligands have variable 
affinity for the receptor and may invoke differential responses. For 
example, the relatively low affinity ligand H60c is constitutively 
(and exclusively) expressed in the skin without evoking apparent 
cytotoxicity in vivo although it could induce cytotoxicity in γδ 
IEL cell lines in vitro (25). Moreover, while inducible expression 
of the high affinity Rae-1 ligand in the epidermis in vivo clearly 
activates the epidermal γδ IEL (Figure 1Bii) no overt cytotoxicity 
of the ECs was observed (4). Rather, a possible role for NKG2D-
ligation in EC repair was indicated as this pathway was shown to 
induce potent expression of type 2 cytokines, particularly IL-13, 
from the γδ IEL, which functions to potentiate EC turnover, 
maintain an intact barrier, and thereby enhance resistance to 
carcinogenesis (26, 27). Further, Rae-1 transcripts were initially 
reported in mouse embryonic tissues and NKG2D ligands are 
also expressed in cells of the bone marrow (28, 29). Interestingly, 
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FiGURe 1 | NKG2D ligands and a timely response to alteration in their expression by epidermal γδTCR+ intraepithelial lymphocytes (IELs). (A) Human and mouse 
NKG2D ligands, their cell surface anchor and their affinity to NKG2D are shown. (B) Representative confocal images of murine epidermal Vγ5Vδ1+ lELs in whole 
epidermal sheets following transgenic upregulation of Rae-1 under the involucrin promoter. (i) Single-transgenic and (ii) bi-transgenic mice were fed with doxycycline 
for 72 h, inducing expression of Rae-1 only in bi-transgenic mice (4). (iii) Mice with sustained expression of Rae-1 under the involucrin promoter (19). The images 
depict how acute expression of Rae-1 on epithelial cells induces morphological and activational changes in the neighboring IELs, whereas constitutive expression  
of Rae-l renders them hyporesponsive. Abbreviations: *allele-dependent NKG2D, natural killer group 2 member D; MIC, MHC class I-chain-related protein; ULBP, 
cytomegalovirus UL16-binding protein; Rae-1, retinoic acid early-inducible 1; MULT1, murine UL16-binding protein-like transcript 1; al, a2, and a3, analogous to  
the a1, a2, and a3 domains of MHC 1a proteins; TM, transmembrane protein; GPl, glycosylphosphatidylinositol-linked protein; ND, not determined.
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pregnancy, which may be sensed by uterine NK cells (which are 
not cytolytic). Together these observations suggest that NKG2D-
ligand expression does not always evoke cytotoxicity in vivo, but 
may have an additional and relatively unexplored role in develop-
ment and/or tissue repair.
nKG2D-DePenDenT ACTivATiOn  
OF HUMAn γδ T CeLLS
Most (60–95%) human peripheral blood γδ T cells express Vγ9Vδ2 
TCRs that are uniquely activated by non-peptidic prenyl pyroph-
osphate antigens (phosphoantigens, PAg) such as isopenthenyl 
pyrophosphate, which is abundant in tumor cells; or (E)-4-hydroxy-
3-methyl-but-enyl pyrophosphate, that is produced by bacteria and 
parasites [reviewed in Ref. (30)]. PAg-activated Vγ9Vδ2 T  cells 
play important protective roles in infections, such as tuberculosis 
(31–34); and can kill a variety of tumor cell lines (35, 36).
Recent research has clarified how PAg may be “sensed” by 
Vγ9Vδ2 TCRs. This involves butyrophilin 3A1 (BTN3A1; also 
known as CD277), a B7 superfamily member that binds PAg in 
its intracellular B30.2 domain, which leads to significant con-
formational changes in the extracellular domains of the protein 
(37–43). Importantly, the effects of both agonist and blocking 
anti-BTN3A1 mAbs on Vγ9Vδ2 TCR transductants indicated 
that the TCR is necessary for the activation process (44, 45).
Besides TCR-dependent sensing of intracellular PAg accumu-
lation, the discrimination between tumor and healthy cells by 
Vγ9Vδ2 T cells seemingly also involves NKG2D, which is expre ssed 
on the cell surface of nearly all Vγ9Vδ2 T cells, as it is on peripheral 
CD8+ αβ T cells. We have observed that NKG2D blockade reduces 
by circa 50%, the capacity of (PAg-activated) Vγ9Vδ2 T cells to 
target leukemic cells (as measured by apoptosis induction in vitro) 
(5). Moreover, when we looked for NKG2D ligands whose expres-
sion could account for leukemia cell recognition, we found ULBP1 
to be the strongest candidate (5, 35). Consistent with this, the 
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downregulation of ULBP1 impaired, whereas its overexpression 
enhanced, Vγ9Vδ2 T cell-mediated killing of leukemia/lymphoma 
cells (5). In independent studies, other NKG2D ligands have 
emerged as major determinants of tumor cell targeting by γδ 
T cells: ULBP4 in ovarian and colon carcinomas (46); and ULBP3 
in B-cell chronic lymphocytic leukemia (CLL) (47). In the latter 
report, the critical γδ T cell subpopulation were Vδ1+ (rather than 
Vδ2+) T cells and Vδ1+ T cell counts as well as detectable/inducible 
ULBP3 expression both associated positively with disease control in 
CLL patients (47). Along the same lines, a recent study showed that 
ULBP1 and NKG2D expression associated (positively) with longer 
overall survival of gastric cancer patients (48). Thus, enhancement 
of NKG2D ligand expression, as achieved by bortezomib or temo-
zolomide treatment of multiple myeloma (49) and glioblastoma 
multiforme (50) cells, respectively, may have important therapeu-
tic potential, even if NKG2D ligand shedding may constitute an 
important immune evasion mechanism (51). On the other hand, 
tumor-directed recombinant ligands that engage NKG2D may 
also enhance tumor cell targeting, as recently documented against 
malignant B cells for bispecifics composed of CD20-binding and 
NKG2D ligand (MICA or ULBP2) domains (52).
The relative importance of NKG2D versus TCR stimulation of 
γδ T cells in human is still debated (53). Some studies reported 
the ability of Vγ9Vδ2 T cells to trigger effector responses through 
NKG2D stimulation alone (i.e., similarly to NK cells) (36, 54, 55). 
However, others have failed to show NKG2D-induced activation 
without simultaneous TCR stimulation (56). In this later case, 
NKG2D would function in γδ T  cells like in CD8+ αβ T  cells, 
i.e., as a costimulatory receptor accessory to the TCR. Future 
research should clarify whether the capacity to deploy NKG2D 
independently of the TCR varies between Vδ2+ versus Vδ1+ 
γδ T cells. The latter are preferentially found in mucosal tissues 
and can often be more abundant than Vδ2+ T cells within solid 
tumors (57). Unlike Vγ9Vδ2 T cells, Vδ1+ T cells do not recog-
nize PAg; instead, intestinal epithelial Vδ1+ T cells were shown to 
bind MICA (and MICB) via a diverse set of Vδ1+ TCRs (58, 59), 
including on transfectants lacking NKG2D (60). Interestingly, 
our own data have identified a key difference between Vδ2+ and 
Vδ1+ T cells with regards to the ability to enhance their cytotoxic 
potential through the upregulation of a distinct class of NK cell 
receptors—the NCRs.
inDUCeD nCRs On HUMAn vδ1+  
T CeLLS
In contrast with NKG2D, NCRs were until recently thought to 
be NK-specific. However, reports on the acquisition of NCR 
expression by activated IELs (9, 10), and the subsequent iden-
tification of ILCs constitutively expressing NCRs, particularly 
NKp46 (8), have clearly demonstrated that NCR expression is 
not an exclusive property of NK cells. Although mouse γδ T cells 
seemingly do not express NKp46, we reported that the continued 
(>2 weeks) activation by TCR agonists (or mitogens-like PHA) 
in the presence of IL-15 or IL-2 induced NCR expression in a 
large fraction (>50%) of human γδ T cells (11). Interestingly, 
NCR induction was mostly restricted to Vδ1+ T cells, as Vδ2+ 
T  cells failed to express any of the NCRs above background 
levels. And, in Vδ1+ T  cells, the main induced NCRs were 
NKp30 and NKp44, with NKp46 limited to a smaller fraction 
(<20%) of activated cells. Antibody-mediated modulation and 
redirected lysis assays demonstrated the capacity of NKp30 and, 
to a lesser extent, NKp44, but not NKp46, to enhance Vδ1+ 
T cell cytotoxicity against tumor cell targets (11). Furthermore, 
NCR triggering increased IFN-γ expression in Vδ1+ T  cells, 
consistent with their role in NK  cells (61). Based on these 
findings, we have developed and established the pre-clinical 
proof-of-concept for a new (NCR+ Vδ1+) cellular product, delta 
one T (DOT) cells, for adoptive immunotherapy of cancer (12) 
(Figure 2). Moreover, we also demonstrated that this NKp30-
mediated activation of Vδ1+ T cells was able to inhibit HIV viral 
replication, through the production of CCL3/MIP-1α, CCL4/
MIP-1β, and CCL5/RANTES (62). These three CC-chemokines 
can inhibit viral replication by binding to CCR5, one of the pri-
mary co-receptors that HIV-1 uses for entry into CD4+ T cells. 
Collectively, these studies showed that the induced expression of 
NCRs on Vδ1+ T cells enhances their anti-tumor and anti-viral 
functions.
The acquisition of NCR expression by peripheral blood 
Vδ1+ T cells strictly requires strong TCR activation (11). This is 
consistent with previous work on human IELs, since the ability 
to upregulate NKp46 and NKp44 in the gut environment only 
occurred in effector T cells, and the expanded population of NCR+ 
αβ IELs in celiac disease displayed a highly restricted TCR reper-
toire indicative of oligoclonal expansion (10). Thus, the major cur-
rent working hypothesis is that the expression of NCRs in T cells 
may derive from chronic activation via the TCR. This may allow 
pre-activated T  lymphocytes to circumvent antigen-restricted 
responses, instead employing NCRs to respond continuously 
against “danger” or “stress,” which clearly fits the concept of LSS 
by γδ T cells (4, 20, 21).
In this context, it will be critical to identify the NCR ligands 
that are relevant to NCR+ Vδ1+ T cell biology, presumably associ-
ated with the processes of cellular transformation or viral infec-
tion. Thus, the hemagglutinin (HA) protein of the influenza and 
vaccinia virus binds NKp46 to stimulate NK cells to lyse virus-
infected cells (63, 64). Conversely, a HCMV protein, pp65, was 
reported to inhibit NK cytotoxicity by dissociating the signaling 
chain, CD3ζ, from its complex with NKp30 (65).
Self-derived molecules have also been identified as ligands 
for NCRs, which underlies their capacity to target tumor and/or 
stressed cells. One of the first self-molecules identified to inter-
act with NKp30 is the human leukocyte antigen-B-associated 
transcript 3 (BAT3) (66). The expression of this molecule on 
the tumor cell surface triggers NKp30-mediated killing and the 
production of IFN-γ and TNF-α. The anti-tumor role of BAT3 
was confirmed in vivo by showing that peripheral blood NK cells 
were less efficient at clearing tumors when an anti-BAT3 blocking 
antibody was administered in mice.
A member of the B7 receptor family, B7-H6, was also shown 
to bind NKp30 (67). B7-H6 is present on cell surface of both 
primary tumor and tumor cell lines, while neither healthy nor 
stressed cells seemingly expressing it. Interestingly, while the 
presence of B7-H6 on the surface of tumor cells makes them 
FiGURe 2 | NK cell receptors and ligands for delta one T (DOT) cells. DOT cells are expanded/activated Vδ1+ T cells that upregulate NKG2D and DNAM-1 levels, 
and induce de novo NKp30 and NKp44 expression [(A) from Ref. (12)]. (B) The figure depicts putative ligands for those NK cell receptors known to be (over) 
expressed on tumor cells.
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susceptible to NKp30-mediated killing (67), the binding of B7-H6 
to the alternative splice variant, NKp30c, reduces cytotoxicity 
and IFN-γ production, instead inducing NK cells to produce the 
immunoregulatory cytokine IL-10 (68). Moreover, the expression 
of the NKp30c isoform associated with poor clinical prognosis in 
gastrointestinal sarcoma.
As for NKp44, until recently its best-characterized ligand was 
an inhibitory molecule, proliferating cell nuclear antigen, that is 
commonly expressed by tumor cells, and strongly inhibited by 
NK cell cytotoxicity and IFN-γ production, likely via the inhibi-
tory ITIM motif atypically present in the intracellular domain of 
NKp44 (69). However, a very recent study showed that NKp44 
binds to platelet-derived growth factor-DD, a key promoter of 
tumor cell proliferation, epithelial–mesenchymal transition, and 
angiogenesis (70). The interaction provoked NK cell activation 
and the secretion of IFN-γ and TNF-α, which induced tumor 
cell growth arrest, including in in vivo cancer models. This may 
be a seminal finding in our understanding of how immune cells 
can recognize tumor cells. Future research should clarify the 
repertoire of NCR ligands that underlie the enhanced anti-tumor 
functions of NCR+ Vδ1+ T cells (Figure 2).
COnCLUSiOn AnD PeRSPeCTiveS
Our current working model includes two stages of γδ T cell acti-
vation and target cell recognition: first, γδ T cells are activated by 
γδTCR ligands (many of which are still unknown); but then NKRs 
may play the key role in identifying stressed (transformed or 
infected) targets. This role is physiologically fulfilled by NKG2D 
(25), constitutively expressed by γδ T cells (3, 4); but therapeutically 
it can rely on induced NCRs, particularly for the human Vδ1+ T cell 
subset whose clinical potential is still to be realized (57). For these, 
the expression of both NKG2D and NCRs provides two functional 
layers of innate stress-surveillance, particularly of tumors. From a 
clinical perspective, we have established a clinical-grade protocol 
to differentiate NCR+ Vδ1+ T cells in vitro, from peripheral blood 
of cancer patients, toward the development of a new adoptive cell 
immunotherapy (“DOT cells”) (12). Of note, concomitant with 
TCR stimulation, IL-15 seems to be the key cytokine for NCR 
induction on Vδ1+ T cells (12), which is consistent with previous 
data on NK cells and IELs (61). Given that the gut is an IL-15-rich 
environment, it will be interesting to investigate the expression of 
NCRs on intestinal γδ T cells, especially since these compose a 
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large fraction of the IEL compartment; and are highly enriched 
in Vδ1+ (compared to Vδ2+) T cells. Such future research should 
also clarify the enigmatic role of NKp46, since it was not evident 
from our studies on blood-derived Vδ1+ T cells (12); and address 
the potential relevance of NCRs for the reported regulatory func-
tions of Vδ1+ TILs (71, 72).
Besides cancer, another potential application for NCR+ Vδ1+ 
T cells is the control of viral infection. Our demonstration that 
NKp30 engagement on in vitro activated Vδ1+ T cells is able to 
suppress HIV-1 replication through the production of CCL3/
MIP-1α, CCL4/MIP-1β, and CCL5/RANTES, opens new avenues 
for the manipulation of γδ T cells in HIV-1 disease. This is par-
ticularly interesting because HIV-1 infection is characterized by 
a marked expansion of Vδ1+ T cells (73–75). This may be even 
more relevant in mucosal tissues, namely intestinal and cervical 
mucosa that are sites of HIV-1 entry, where Vδ1+ T cells are par-
ticularly abundant (76), while CD4+ T cells are strongly depleted 
(77). Of additional great potential is the use of NCR+ Vδ1+ T cells 
in CMV infection, given the well-established anti-CMV activity 
and long-term expansion of Vδ1+ T cells (78–81), including post-
allogeneic stem cell transplantation (80–81).
In conclusion, we propose that NK cell receptor expression by 
γδ T cells contributes decisively to their role as a “bridge” between 
innate and adaptive immunity, both physiologically (via consti-
tutive NKG2D) and therapeutically (through induced NCRs). 
We believe this entails great potential for future γδ T cell-based 
immunotherapies against viral infections or cancer.
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